SMS Pharmaceuticals Limited (SMS Pharma) (NSE: SMSPHARMA; BSE:532815) has received the EUGMP certification for its Visakhapatnam (Vizianagaram) facility after a successful inspection during 28th February 2024 to 01st March 2024 for its Ibuprofen dossier. The inspection conducted by European Directorate for the Quality of Medicines & HealthCare (EDQM) at its Visakhapatnam facility confirmed its compliance with Quality Management System based on Good Manufacturing Practices as laid down in the EU Rules Governing Medical Products in the European Union.
Commenting on this achievement, Mr. P. Vamsi Krishna, Executive Director, stated: "We are proud to receive the EDQM certification, which reflects our commitment to quality and compliance with global standards, and pursuing market leadership in our select APIs globally. It is a testament to our team's dedication and hard work, further solidifying our position as a trusted partner in the pharmaceutical industry."
Shares of SMS Pharmaceuticals Limited was last trading in BSE at Rs. 374.75 as compared to the previous close of Rs. 351.25. The total number of shares traded during the day was 131923 in over 3041 trades.
The stock hit an intraday high of Rs. 376.85 and intraday low of 351.95. The net turnover during the day was Rs. 48806494.00.